In this article, we also introduced the observation of DMRs unique to patients with COVID-19, which may serve as biomarkers for predicting the disease severity and the possibility of functioning as a novel therapeutic agent by epigenetically regulating ACE2 expression. This evidence concerns the gene ACE2 and COVID-19.